Taiwan Liposome Co (台灣微脂體), a developer of generic drugs used to treat breast and ovarian cancer, on Thursday said it had signed a research agreement with Belgian biotechnology company Ablynx NV.
Under their collaboration, the two firms will evaluate the potential of a novel antibody drug conjugate combining Taiwan Liposome’s immunoliposome drug delivery platform with Ablynx’s proprietary “Nanobody” drug technology.
Eventually, they hope to develop a product that has enhanced abilities to target and deliver cancer-killing drug payloads.
NANOBODIES
Ablynx is engaged mainly in the development of nanobodies, a novel class of therapeutic proteins based on single-domain antibody fragments, for treatment of inflammation, hematology, oncology and pulmonary diseases, according to information posted on the company’s Web site.
Using antibody drug conjugates to treat various types of cancer in recent years is aimed at generating fewer side effects, like hair loss, nausea and low blood pressure, than the older ways of using drugs.
DELIVERY TECHNOLOGY
Having worked on drug delivery technology since its establishment in 1997, Taiwan Liposome views using antibody drug conjugates as having great potential to increase efficacy in cancer and immune system treatments.
“Antibody drug conjugates have brought much excitement to the healthcare industry by combining the targeting specificity of antibodies with the efficacy of cytotoxic compounds,” company president George Yeh (葉志鴻) said in a press release.
“Our immunoliposome platform can drastically enhance the therapeutic value by carrying a much higher payload amount,” Yeh said. “This collaboration with Ablynx marks the starting point of infinite development possibilities for this technology platform.”
NO IMPACT
Yuanta Securities Group (元大證券) analyst Peggy Lee (李珮菁) yesterday said the collaboration is built on a feasibility study and is not expected to have a significant impact on the two firms in the short term, although they may receive milestone payments and royalties in the long term.
In the first three months of the year, Taiwan Liposome reported NT$35.99 million (US$1.19 million) in sales, down 53.39 percent from the same period last year, according to a company filing to the Taiwan Stock Exchange.
UNDERPERFORMING
Taiwan Liposome shares dropped 2.05 percent to NT$263 yesterday. They have declined 23.77 percent since the beginning of the year, underperforming the GRETAI, which has risen 12.18 percent over the same period.
To many, Tatu City on the outskirts of Nairobi looks like a success. The first city entirely built by a private company to be operational in east Africa, with about 25,000 people living and working there, it accounts for about two-thirds of all foreign investment in Kenya. Its low-tax status has attracted more than 100 businesses including Heineken, coffee brand Dormans, and the biggest call-center and cold-chain transport firms in the region. However, to some local politicians, Tatu City has looked more like a target for extortion. A parade of governors have demanded land worth millions of dollars in exchange
Hong Kong authorities ramped up sales of the local dollar as the greenback’s slide threatened the foreign-exchange peg. The Hong Kong Monetary Authority (HKMA) sold a record HK$60.5 billion (US$7.8 billion) of the city’s currency, according to an alert sent on its Bloomberg page yesterday in Asia, after it tested the upper end of its trading band. That added to the HK$56.1 billion of sales versus the greenback since Friday. The rapid intervention signals efforts from the city’s authorities to limit the local currency’s moves within its HK$7.75 to HK$7.85 per US dollar trading band. Heavy sales of the local dollar by
Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) revenue jumped 48 percent last month, underscoring how electronics firms scrambled to acquire essential components before global tariffs took effect. The main chipmaker for Apple Inc and Nvidia Corp reported monthly sales of NT$349.6 billion (US$11.6 billion). That compares with the average analysts’ estimate for a 38 percent rise in second-quarter revenue. US President Donald Trump’s trade war is prompting economists to retool GDP forecasts worldwide, casting doubt over the outlook for everything from iPhone demand to computing and datacenter construction. However, TSMC — a barometer for global tech spending given its central role in the
An Indonesian animated movie is smashing regional box office records and could be set for wider success as it prepares to open beyond the Southeast Asian archipelago’s silver screens. Jumbo — a film based on the adventures of main character, Don, a large orphaned Indonesian boy facing bullying at school — last month became the highest-grossing Southeast Asian animated film, raking in more than US$8 million. Released at the end of March to coincide with the Eid holidays after the Islamic fasting month of Ramadan, the movie has hit 8 million ticket sales, the third-highest in Indonesian cinema history, Film
RSS